Af­ter a 5-year re­peat PhI­II so­journ, Lund­beck and Ot­su­ka say they're fi­nal­ly ready to pur­sue OK to use Rex­ul­ti against Alzheimer's ag­i­ta­tion

Five years af­ter Lund­beck and their long­time col­lab­o­ra­tors at Ot­su­ka turned up a mixed set of Phase III da­ta for Rex­ul­ti as a treat­ment for Alzheimer’s de­men­tia-re­lat­ed ag­i­ta­tion, they’ve come through with a new piv­otal tri­al suc­cess they be­lieve will fi­nal­ly put them on the road to an ap­proval at the FDA. And if they’re right, some an­a­lysts be­lieve they’re a short step away from adding more than $500 mil­lion in an­nu­al sales for the drug, al­ready ap­proved in de­pres­sion and schiz­o­phre­nia.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER